Marker Therapeutics Inc (MRKR)

[microcapbiotech]

OK, like my head is going to explode, they, delayed the adjuvant group, changed the active group design.

I am sorry for questions, but I will ask.

SPECIFICALLY talking about one thing: "The new nine-day manufacturing process enables increased antigen specificity and diversity, the new process produces a patient product that is four times more potent, with the potential to greatly improve tumor killing."

OK, in relation to that Statement;

Is THAT the "medicine/treatment" that was given to the one MRD positive patient and five frank relapse patients in the safety lead-in stage of the Marker Phase 2 AML trial?

Did they delay the adjuvant group because they want to use the new "9 day, 4 times more potent" medicine/treatment in further adjuvant procedures?

And also, if the 5 frank relapse patients, the way I read it, were "frank" when they were given to us, as in they had ALREADY relapsed BEFORE MT-401 who knows how many times and from who knows how many different drugs and treatments, and therefore (I assume) must have been sick for a long time ... in other words, weren't the chances for "curing" very sick, already relapsed patients very small to start with?

How many already relapsed frank patients have others "cured"?